Literature DB >> 28671022

Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma.

Wenhui Ge1, Jing Li2, Wenhao Fan2, Delong Xu2, Shangfei Sun1.   

Abstract

Osteosarcoma is the most frequent primary bone tumor that affects adolescents and children. However, diagnostic and prognostic biomarkers for osteosarcoma remain lacking. (Tim-3) T-cell immunoglobulin domain and mucin domain-3, which negatively regulates T cell helper (Th1) cells and affects cytokine expression, has attracted increasing attention due to its critical role in regulating both adaptive and innate immune cells. In this study, we evaluated serum soluble Tim-3 level in osteosarcoma patients to explore its diagnostic and prognostic value for this particular malignancy. Serum soluble Tim-3 level was measured with enzyme-linked immunosorbent assay in 120 osteosarcoma patients, 120 benign bone tumors patients and 120 healthy controls, followed by analysis of the correlation with clinic pathological characteristics. Receiver operating curves, Kaplan-Meier curves, and log-rank analyses as well as Cox proportional hazard models were used to evaluate the diagnostic and prognostic significance. Serum solubleTim-3 level was remarkably elevated in osteosarcoma patients. Osteosarcoma patients with larger tumor size, late stages and distant metastases were accompanied with higher levels of Tim-3. ROC/AUC analysis indicated thatTim-3 served as a reliable marker to distinguish healthy participants from Tim-3 patients. Osteosarcoma patients with higher Tim-3 had relatively lower survival. Multivariate analyses for overall survival revealed that high serum soluble Tim-3 level was an independent prognostic factor for osteosarcoma. Furthermore, Tim-3 levels of CD8+ and CD4+ T cells were elevated in peripheral circulation of osteosarcoma patients. Therefore, It was indicated in our research that elevated serum soluble Tim-3 level might be a novel potential diagnostic and prognostic biomarker for osteosarcoma patients.

Entities:  

Keywords:  Tim-3; biomarker; diagnosis; osteosarcoma; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28671022     DOI: 10.1177/1010428317715643

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

1.  Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity.

Authors:  Antonio Riva; Elena Palma; Dhruti Devshi; Douglas Corrigall; Huyen Adams; Nigel Heaton; Krishna Menon; Melissa Preziosi; Ane Zamalloa; Rosa Miquel; Jennifer M Ryan; Gavin Wright; Sarah Fairclough; Alexander Evans; Debbie Shawcross; Robert Schierwagen; Sabine Klein; Frank E Uschner; Michael Praktiknjo; Krum Katzarov; Tanya Hadzhiolova; Slava Pavlova; Marieta Simonova; Jonel Trebicka; Roger Williams; Shilpa Chokshi
Journal:  Front Physiol       Date:  2021-03-10       Impact factor: 4.566

2.  Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy.

Authors:  Ming Chen; Liang Wang; Yigang Wang; Xiumei Zhou; Xinyuan Liu; Hao Chen; Biao Huang; Zhigang Hu
Journal:  J Clin Lab Anal       Date:  2020-02-20       Impact factor: 2.352

3.  Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma.

Authors:  Youngji Kim; Eisuke Kobayashi; Yoshiyuki Suehara; Ayumu Ito; Daisuke Kubota; Yoshikazu Tanzawa; Makoto Endo; Fumihiko Nakatani; Tetsuya Nakatsura; Akira Kawai; Kazuo Kaneko; Shigehisa Kitano
Journal:  Oncol Lett       Date:  2021-01-18       Impact factor: 2.967

4.  Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.

Authors:  John A Ligon; Woonyoung Choi; Gady Cojocaru; Wei Fu; Emily Han-Chung Hsiue; Teniola F Oke; Nicholas Siegel; Megan H Fong; Brian Ladle; Christine A Pratilas; Carol D Morris; Adam Levin; Daniel S Rhee; Christian F Meyer; Ada J Tam; Richard Blosser; Elizabeth D Thompson; Aditya Suru; David McConkey; Franck Housseau; Robert Anders; Drew M Pardoll; Nicolas Llosa
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

5.  The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration.

Authors:  Jiahua Li; Hui Shi; Zhanyuan Yuan; Zhiheng Wu; Haohao Li; Yuelong Liu; Ming Lu; Ming Lu
Journal:  BMC Cancer       Date:  2022-01-25       Impact factor: 4.430

6.  The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.

Authors:  Noel E Donlon; Maria Davern; Andrew D Sheppard; Fiona O'Connell; Margaret R Dunne; Conall Hayes; Eimear Mylod; Sinead Ramjit; Hugo Temperley; Michael Mac Lean; Gillian Cotter; Anshul Bhardwaj; Christine Butler; Melissa J Conroy; Jacintha O'Sullivan; Narayanasamy Ravi; Claire L Donohoe; John V Reynolds; Joanne Lysaght
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

7.  A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer.

Authors:  Ying Peng; Chen Zhang; Zhilian Rui; Weiming Tang; Yan Xu; Xiaoxin Tao; Qi Zhao; Xin Tong
Journal:  J Clin Lab Anal       Date:  2022-01-12       Impact factor: 2.352

8.  TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation.

Authors:  Kui Zang; Liangliang Hui; Min Wang; Ying Huang; Xingxing Zhu; Bin Yao
Journal:  Front Oncol       Date:  2021-02-22       Impact factor: 6.244

Review 9.  On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.

Authors:  Sai Mummareddy; Stuti Pradhan; Ashwin Kumar Narasimhan; Arutselvan Natarajan
Journal:  Biosensors (Basel)       Date:  2021-12-07

10.  Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment.

Authors:  Guodong Liao; Ping Wang; Yuyong Wang
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.